GM1 Reduced the Symptoms of Autism Spectrum Disorder by Suppressing α-Syn Through Activating Autophagy

J Mol Neurosci. 2023 May;73(4-5):287-296. doi: 10.1007/s12031-023-02110-5. Epub 2023 Apr 21.

Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that cannot be cured. The ASD rat model was developed in this study to demonstrate the role and mechanism of ganglioside GM1 (GM1). Rats were given valproic acid (VPA) to create the ASD rat model. The rats' behaviors were assessed using the Y-maze test, open-field test, three-chamber social interaction test, and Morris water maze test. Relative levels of glutathione (GSH), malondialdehyde (MDA), catalase (CAT), reactive oxygen species (ROS), and superoxide dismutase (SOD) were quantitated using relative kits. Nissl, TUNEL, immunofluorescent, and immunohistochemistry staining techniques were used. GM1 treatment improved the ASD model rats' behavior disorders, including locomotor activity and exploratory behavior, social interaction, learning and memory capacity, and repetitive behavior. Following GM1 injection, striatal neurons grew and apoptosis decreased. GM1 reduced the excessively elevated α-Syn in ASD by encouraging autophagy. The behavior disorder of ASD model rats was exacerbated by autophagy inhibition, which also increased α-Syn levels. By increasing autophagy, GM1 reduced α-Syn levels and, ultimately, improved behavioral abnormalities in ASD model rats.

Keywords: ASD; Autophagy; GM1; α-Syn.

MeSH terms

  • Animals
  • Autism Spectrum Disorder* / drug therapy
  • Autophagy
  • Disease Models, Animal
  • Female
  • G(M1) Ganglioside / pharmacology
  • G(M1) Ganglioside / therapeutic use
  • Humans
  • Maze Learning
  • Prenatal Exposure Delayed Effects*
  • Rats
  • Social Behavior
  • Valproic Acid / pharmacology

Substances

  • G(M1) Ganglioside
  • Valproic Acid